2009-11-06 13:11:10 -

King Pharmaceuticals, Inc. (NYSE:KG) today announced plans to provide a live webcast of its presentation scheduled for Thursday, November 12, 2009, at 9:00 am Mountain Standard Time (11:00 am Eastern Standard Time), at the Credit Suisse 2009 Healthcare Conference at the Arizona Biltmore Hotel in Phoenix, Arizona. The presentation may include a discussion of the Company’s marketed products, pipeline, strategy for growth, financial results and expectations, and other matters relating to its business.

Interested persons may access the live webcast via the internet on the King Pharmaceuticals website at the following link: www.kingpharm.com/Investors/Webcasts.cfm : .

A replay of the webcast may be accessed at this same link for a period of not less than 14 days after the live

event.



About King Pharmaceuticals, Inc.

King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products and technologies that complement the Company’s focus in specialty-driven markets, particularly neuroscience and hospital. King's wholly-owned subsidiary, Alpharma, Inc., is also a leader in the development, registration, manufacture and marketing of pharmaceutical products for food producing animals.


About Forward-looking Statements

This release contains forward-looking statements which reflect management’s current views of future events and operations, including, but not limited to, statements pertaining to the anticipated webcast of the Company’s presentation on November 12, 2009. These forward-looking statements involve certain significant risks and uncertainties, and actual results may differ materially from the forward-looking statements. An important factor which may cause results to differ is whether King is able to webcast the presentation on November 12, 2009 as currently planned. King does not undertake to publicly update or revise any of its forward-looking statements even if experience or future changes show that the indicated results or events will not be realized.

EXECUTIVE OFFICES

KING PHARMACEUTICALS, INC.

501 FIFTH STREET, BRISTOL, TENNESSEE 37620

King Pharmaceuticals, Inc.Jack Howarth, Vice President, Investor

Relations, 908-429-8350